[Chemoradiotherapy in head and neck squamous cell carcinoma: focus on targeted therapies].
Radiotherapy is an essential treatment for many patients with head and neck squamous cell carcinoma. Its association with molecular targeted therapies represents a real progress. Among the recent advances in the molecular targeted therapy of cancer, the applications centred on EGFR are currently the most promising and the most advanced at clinical level. Considering the set of therapeutic tools targeting EGFR, there are at present two well-identified emerging categories of drugs with monoclonal antibodies, on the one hand, and tyrosine kinase inhibitors, on the other. In many preclinical studies, the combination of anti-EGFR drugs with irradiation has led to additive or supra-additive cytotoxic effects. Furthermore, antiangiogenic agents have shown promising results in association with anti-EGFR drugs and radiotherapy. This research effort has recently produced encouraging clinical results in advanced head and neck cancer with combination of cetuximab (an anti-EGFR monoclonal antibody) with irradiation with a significant impact on patient survival. Active and efficient clinical research is currently ongoing to determine the place of molecular targeted therapies in the treatment of head and neck cancer, particularly in association with radiotherapy.
Bozec
A
A
Département de Chirurgie, Institut Universitaire de la Face et Du Cou, Centre Antoine-Lacassagne, 33, avenue de Valombrose, Nice, France. alexandre.bozec@nice.fnclcc.fr
Thariat
J
J
Bensadoun
R J
RJ
Milano
G
G
D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006258:Head and Neck Neoplasms / Q000098:blood supply / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D018714:Radiotherapy, Adjuvant; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D018719:Erb-b2 Receptor Tyrosine Kinases